摘要
目的:探讨p16、nm 23H 1在淋巴瘤组织的表达及其与淋巴瘤临床病理特征、疗效、生存率的关系,从而为临床治疗和判断预后提供新的依据。方法:采用免疫组化S-P法。结果:1.霍奇金淋巴瘤(HL)及非霍奇金淋巴瘤(NHL)p16、nm 23H 1表达差异无显著性。2.随淋巴瘤恶性程度的升高,p16表达减弱,nm 23H 1表达增强(P<0.01)。3.p16低表达组完全缓解(CR)率低于p16高表达组,nm 23H 1低表达组CR率高于高表达组,差异均有显著性(P<0.05)。4.p16高表达组与p16低表达组生存率差异无显著性(P>0.05),nm 23H 1低表达组生存率高于nm 23H 1高表达组(P<0.01)。结论:p16、nm 23H 1表达水平不仅可反映淋巴瘤的恶性程度,而且可作为淋巴瘤的预后指标。
Objective： To detect the expression of p16, nm23H1 in malignant lymphoma cells and to elucidate its relation to the clinicopathological characteristics, chemotherapeutic response and survival rate, and therefore to provide a new theoretical basis for clinical treatment and predicting prognosis. Methods： Immunohistochemical technique, S-P method was used. Results： 1. There is not statistically significant difference between the expression of p16, nm23H1 in HL and that in NHL（ P〉0. 05）. 2. The expression of p16 was weakened, while the expression of nm23H1 was enhanced with the increase in the level of malignancy in NHL（ P〈0.01）. 3. The CR rate in patients with high expression of p16 was far better than that in patients with low expression of p16 （P 〈0. 05）; the CR rate in patients with high expression of nm23H1 was far worse than that in patients with low expression of nm23H1 （ P 〈0.05）. 4. The difference of survival rate between the group with p16 high expression and that with p16 low expression was not significant （ P〉0. 05）;the survival rate in the group with nm23H1 low expression was significantly higher than that in the group with nm23H1 high expression （ P 〈0. 01）. Conclusion： p16, nm23H1 expression levels in malignant lymphoma can not only reflect its level of malignancy but also predict the prognosis.
出处
《内蒙古医学院学报》
2006年第2期102-105,共4页
Acta Academiae Medicinae Neimongol
